Guillain-Barre Syndrome Diagnostics Market Size, Share & Trends Report By Test (Lumbar Puncture, Electromyography), By End-use (Hospitals And Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

Guillain-Barre Syndrome Diagnostics Market Growth & Trends

The global guillain-barre syndrome diagnostics market size is expected to reach USD 169.9 million by 2030, registering a CAGR of 2.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. driven by several key factors. A significant contributor is the increasing incidence of Guillain-Barre syndrome (GBS), particularly in regions with high rates of infectious diseases. Infections such as respiratory or gastrointestinal illnesses often precede GBS, leading to a heightened demand for effective diagnostic tools. For instance, a study from the University of Minnesota in October 2023 highlighted that 67% of GBS cases were preceded by such infections, underscoring the need for timely diagnosis.

Advancements in diagnostic techniques have also played a crucial role in market expansion. Innovations in electromyography (EMG) and nerve conduction studies have enhanced the accuracy and speed of GBS diagnosis. These technological improvements enable healthcare professionals to detect the syndrome earlier, facilitating prompt intervention and better patient outcomes. The integration of advanced diagnostic tools in clinical settings has become increasingly prevalent, reflecting a commitment to improving patient care.

The growing awareness of GBS among healthcare providers and the general population has further propelled the diagnostics market. Educational initiatives and increased information dissemination have led to earlier recognition of symptoms and subsequent diagnostic testing. This heightened awareness ensures that patients receive timely and appropriate care, reducing the risk of severe complications associated with delayed diagnosis. Consequently, the demand for diagnostic services has risen, contributing to market growth.

The expanding geriatric population has influenced the market for GBS diagnostics. Older individuals are more susceptible to infections that can trigger GBS, necessitating effective diagnostic measures. According to the World Health Organization's 2021 forecast, by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. This demographic shift underscores the importance of accessible and accurate diagnostic tools to manage the anticipated increase in GBS cases among the elderly.

Key players in the market are implementing strategic initiatives such as geographical expansion, collaborations, partnerships, and joint ventures to strengthen their market presence.

Guillain-Barre Syndrome Diagnostics Market Report Highlights

  • The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest compound annual growth rate (CAGR) of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis.
  • The end-use segment comprises hospitals & clinics, and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols.
  • Asia Pacific dominated the global market with a revenue share of 41.8% in 2024. Factors such as rising awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Test
1.1.2. End Use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Guillain-Barre Syndrome (GBS) Diagnostics Market Variables, Trends & Scope
3.1. Market Dynamics
3.1.1. Market driver analysis
3.1.2. Market restraint analysis
3.1.3. Market opportunities analysis
3.2. Guillain-Barre Syndrome (GBS) Diagnostics Market Analysis Tools
3.2.1. Industry Analysis - Porter’s
3.2.1.1. Supplier power
3.2.1.2. Buyer power
3.2.1.3. Substitution threat
3.2.1.4. Threat of new entrant
3.2.1.5. Competitive rivalry
3.2.2. PESTEL Analysis
3.2.2.1. Political landscape
3.2.2.2. Economic landscape
3.2.2.3. Social landscape
3.2.2.4. Technological landscape
3.2.2.5. Environmental landscape
3.2.2.6. Legal landscape
3.2.3. COVID-19 Impact Analysis
3.2.4. Case Studies
Chapter 4. Guillain-Barre Syndrome (GBS) Diagnostics Market: Test Estimates & Trend Analysis
4.1. Test Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by Product Test Outlook
4.4. Lumbar Puncture
4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5. Nerve Conduction Studies
4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.6. Electromyography
4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Guillain-Barre Syndrome (GBS) Diagnostics Market: End Use Estimates & Trend Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by End Use Outlook
5.4. Hospitals and Clinics
5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.5. Diagnostic Laboratories
5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Guillain-Barre Syndrome (GBS) Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Test, By End Use
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. Mexico
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Key company market share/position analysis, 2024
7.4. Company Profiles
7.4.1. Cadwell Industries, Inc
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Technology test benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Natus Medical Incorporated
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Technology test benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Nihon Kohden Corporation
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Technology test benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Medtronic plc
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Technology test benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Bionen Medical Devices
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Technology test benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Deymed Diagnostic
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Technology test benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Neurosoft
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Technology test benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Alpine Biomed
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Technology test benchmarking
7.4.8.4. Strategic initiatives
7.4.9. EMS Biomedical
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Technology test benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Rochester Electro-Medical, Inc
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Technology test benchmarking
7.4.10.4. Strategic initiatives

Loading...

In this report,

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings